Stock Analysis, Dividends, Split History

BIVV / Bioverativ Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price104.98
Volume792,900.00
Market Cap ($M)11,361.32
Enterprise Value ($M)10,924.82
Book Value ($M)897.60
Book Value / Share8.29
Price / Book12.66
NCAV ($M)57.60
NCAV / Share0.53
Price / NCAV197.25
Share Statistics
Preferred Stock Shares Outstanding 0
Common Stock Shares Outstanding 108,203,439
Common Shares Outstanding 108,223,644
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.40
Return on Assets (ROA)n/a
Return on Equity (ROE)n/a
Balance Sheet (mrq) ($M)
Assets1,618.30
Liabilities720.70
Quick Ratio1.89
Current Ratio2.00
Income Statement (mra) ($M)
Revenues1,168,500,000.00
Accrued Revenue Related Rebates Current47,900,000.00
Sales Revenue Goods Net1,089,100,000.00
Licenses Revenue79,400,000.00
Operating Income447.20
Net Income355.60
Cash Flow Statement (mra) ($M)
Cash From Operations590.70
Cash from Investing-408.80
Cash from Financing-408.80
Identifiers and Descriptors
CUSIP09075E100
Central Index Key (CIK)1681689
Industry Groups

Split History

Stock splits are used by Bioverativ Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

Related News Stories

Will Roche's (RHHBY) Acquisition Spree Revive the Top Line?

2018-06-21 zacks
Swiss pharma-giant Roche Holdings (RHHBY - Free Report) has been quite active on the acquisition front, of late. Roche, being a leading health care company, focuses on developing and commercializing innovative diagnostic and therapeutic products and services, which help in early detection and prevention of diseases as well as their treatment and monitoring. (46-0)

Sangamo Therapeutics: Investability Outlook

2018-06-13 seekingalpha
Like BioTime (BTX), which we discussed recently, Sangamo (SGMO) is another company that began the wrong way, with a platform, and then, and only recently, moved on to therapeutics. But, oh boy, what a move it has been! The company changed its name from Sangamo Biosciences to Sangamo Therapeutics to emphasize that change in direction after its new CEO Sandy Macrae took over, and within about 24 months, changed from a sleepy lab-oriented laggard to a company with multiple deals and pipeline assets. (68-5)

Alexion-Complement Pharma Tie Up to Treat Neuro Disorders

2018-06-12 zacks
Alexion Pharmaceuticals, Inc. (ALXN - Free Report) announced a partnership with Complement Pharma to co-develop the preclinical C6 complement inhibitor, CP010, for neurodegenerative disorders. (132-0)

Pharma’s Biggest Dealmakers Face More Than M&A Risks - Bloomberg

2018-05-30 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (61-0)

Biogen: Down Too Far, Too Fast?

2018-04-25 seekingalpha
The article reviews reasons that downside risk may be fundamentally manageable (not zero, though), and why it may be attractive technically, as well. (108-0)

CUSIP: 09075E100